Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03729180 · ClinicalTrials.gov registry record · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
A NA study of Surgery, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 1,900
- Enrollment target
- 1
- Study location
NCT03729180 is a NA study of Surgery that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 1,900 participants, below the 52,836-participant average among 120 other Surgery trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03729180, a NA study of Surgery, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,900 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is enrolling adults who are scheduled for either inpatient or outpatient elective surgical procedures at The University of Chicago. At pre-operative visits, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline variants predicting drug response or toxicity risk. Genotyping results will be delivered to participating providers as patient-specific drug-gene clinical decision support summaries using a secured Web portal, the Genomic Prescribing System (GPS). Participating anesthesiologists and critical care and pain management physicians and associated providers from the Department of Anesthesia and Critical Care at the University of Chicago will be invited to receive results for their participating patients. There will be an initial 6- month "run-in" period of the study comprised of approximately 100 enrolled adults in which all patients will have pharmacogenomic results made available to providers. The run-in period will allow for process refinement and GPS delivery to be examined and optimized prior to the randomized phase After the initial run-in period, patients will be randomized to one of two arms - in the pharmacogenomic arm, providers will have access to GPS and pharmacogenomic information, whereas in the control arm, providers will not have access to GPS and patient-specific pharmacogenomic information (current standard of care).
Conditions Studied
Interventions
- PROCEDURE Routine Elective Surgery- In patient or out patient elective surgery
- DIAGNOSTIC_TEST Blood test for genetic testing
- OTHER Drug-genetic Profile
Study Locations (1)
Illinois
- University Of Chicago Medicine Comprehensive Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,900 participants |
| Start Date | 2019-01-22 |
| Est. Completion | 2027-08-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03729180
The ClinicalTrials.gov registry entry for NCT03729180 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,900 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 52,836-participant average among 120 other Surgery trials with a reported enrollment target (96% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Surgery appearing as the primary indexed condition, and to 3 interventions - of which Routine Elective Surgery- In patient or out patient elective surgery is the first listed.
NCT03729180 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT03729180 about?
NCT03729180 is a clinical study titled "The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery". The study is enrolling adults who are scheduled for either inpatient or outpatient elective surgical procedures at The University of Chicago. At pre-operative visits, patients will be consented and a blood sample will be obtained for preemptive genotyping across a panel of actionable germline varia...
What is the current status of trial NCT03729180?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,900 participants. The study started on 2019-01-22. Estimated completion is 2027-08-22.
What conditions does trial NCT03729180 study?
This clinical trial studies the following conditions: Surgery.
What interventions are being tested in trial NCT03729180?
The interventions under investigation include: Routine Elective Surgery- In patient or out patient elective surgery (PROCEDURE), Blood test for genetic testing (DIAGNOSTIC_TEST), Drug-genetic Profile (OTHER).
Who is sponsoring clinical trial NCT03729180?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03729180 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgery
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Use of 3D Technology to Guide Head and Neck Surgery
RECRUITING · NA
-
INCLUDE Program: A Perioperative Wellness Program Tailored for Black Surgical Patients
RECRUITING · NA
-
Ultrasound Evaluation for Improving Patient Selection in vNOTES
RECRUITING · NA
-
Gastric US in ICU Patient
RECRUITING · NA
-
Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery
RECRUITING · NA
-
Physical Therapy After Endometriosis Excision
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.